BioMimetic Therapeutics is widely regarded as the top biotech player in Middle Tennessee. The Nasdaq-traded company led by Founder-CEO Sam Lynch (at left) has come a long way, challenging industry leader Medtronic, and growing from two employees in 2001 to 85 today, with hundreds more high-paying jobs on the way. Recently, an FDA alert related to possible problems with another company's product briefly stampeded BioMimetic shareowners, but the company began recovering, almost immediately. Our Special Report on the Venture Nashville site provides an update on the management team and their strategy for expanding biotech in Nashville. Please click here to read the story.
Friday, May 16, 2008
BioMimetic plots change of course
BioMimetic Therapeutics is widely regarded as the top biotech player in Middle Tennessee. The Nasdaq-traded company led by Founder-CEO Sam Lynch (at left) has come a long way, challenging industry leader Medtronic, and growing from two employees in 2001 to 85 today, with hundreds more high-paying jobs on the way. Recently, an FDA alert related to possible problems with another company's product briefly stampeded BioMimetic shareowners, but the company began recovering, almost immediately. Our Special Report on the Venture Nashville site provides an update on the management team and their strategy for expanding biotech in Nashville. Please click here to read the story.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment